ENDONOVO THERAPEUTICS, INC.

Endonovo Therapeutics (ENDV) has registered zero cyber incidents and zero red-flag 8-K filings in our 90-day monitoring window, suggesting operational stability in the near term. However, the absence of detected events in a short window does not eliminate underlying risk; early-stage biotech firms face persistent dilution pressure and financing dependency that require deeper analysis. Our full 90-day window captures only recent activity—the complete Report extends to 12 months of SEC filings, maps financing history and burn rates, and calculates dilution risk scores that reveal structural vulnerabilities. The full $49 Report adds 12-month filing context, dilution trajectory modeling, and AI-driven risk signals across capital structure and disclosure patterns.